Scholarlink

Purpose <p>To evaluate the real-world efficacy and safety of temozolomide (TMZ) in aggressive and metastatic pituitary neuroendocrine tumors in a Latin American setting, and to address whether TMZ achieves meaningful radiological and biochemical disease control with acceptable toxicity.</p> Methods <p>We conducted a retrospective multicenter study across Brazilian reference centers including patients with aggressive/metastatic pituitary adenomas treated with TMZ and followed for ≥ 6 months. The radiological response was assessed via RECIST 1.1. For functioning pituitary adenomas, biochemical response was assessed using prespecified hormonal criteria. Adverse events were collected from medical records.</p> Results <p>Thirty patients were included (mean age 29.5 years; 53% female). All the tumors were macroadenomas, and 56% were giant (&gt; 4&#xa0;cm). Twenty-one pituitary adenomas were functioning and four were metastatic. Ki-67 was &gt; 3% in 73% of the patients. The mean time from diagnosis to TMZ initiation was 102 months. The radiological disease control rate (partial response or stable disease) was 93.3%. Among functioning tumors, the biochemical disease control rate was 81.2%, with an objective biochemical response rate (complete + partial response) of 68.8%. Adverse events, most commonly nausea and myelotoxicity, occurred in 66% of patients.</p> Conclusion <p>In this multicenter Brazilian real-world cohort, TMZ provided high radiological and biochemical disease control with an acceptable safety profile, suggesting that TMZ is the preferred first-line systemic chemotherapy for aggressive/metastatic pituitary adenomas after the failure of standard therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Isabelle Pinheiro Amaro de Magalhães,
  • Camila Regina Pereira Batista de Macedo,
  • Luciana Ansaneli Naves,
  • Mauro Antonio Czepielewski,
  • Isabella Naves Rosa,
  • Lidiana Bandeira de Santana,
  • Tobias Skrebsky de Almeida,
  • Mario Padula,
  • Paula Condé Lamparelli Elias,
  • Margaret de Castro,
  • Leandro Kasuki,
  • Monica Roberto Gadelha,
  • Carolina Garcia Soares Leães Rech,
  • Heraldo Mendes Garmes,
  • Cesar Luiz Boguszewski,
  • Raquel Soares Jallad,
  • Marilena Nakaguma,
  • Maria Candida Barisson Villares Fragoso,
  • Marcio Carlos Machado,
  • Andrea Glezer,
  • Malebranche Berardo Carneiro da Cunha Neto,
  • Olavo Feher,
  • Rafael Loch Batista

摘要

Purpose

To evaluate the real-world efficacy and safety of temozolomide (TMZ) in aggressive and metastatic pituitary neuroendocrine tumors in a Latin American setting, and to address whether TMZ achieves meaningful radiological and biochemical disease control with acceptable toxicity.

Methods

We conducted a retrospective multicenter study across Brazilian reference centers including patients with aggressive/metastatic pituitary adenomas treated with TMZ and followed for ≥ 6 months. The radiological response was assessed via RECIST 1.1. For functioning pituitary adenomas, biochemical response was assessed using prespecified hormonal criteria. Adverse events were collected from medical records.

Results

Thirty patients were included (mean age 29.5 years; 53% female). All the tumors were macroadenomas, and 56% were giant (> 4 cm). Twenty-one pituitary adenomas were functioning and four were metastatic. Ki-67 was > 3% in 73% of the patients. The mean time from diagnosis to TMZ initiation was 102 months. The radiological disease control rate (partial response or stable disease) was 93.3%. Among functioning tumors, the biochemical disease control rate was 81.2%, with an objective biochemical response rate (complete + partial response) of 68.8%. Adverse events, most commonly nausea and myelotoxicity, occurred in 66% of patients.

Conclusion

In this multicenter Brazilian real-world cohort, TMZ provided high radiological and biochemical disease control with an acceptable safety profile, suggesting that TMZ is the preferred first-line systemic chemotherapy for aggressive/metastatic pituitary adenomas after the failure of standard therapies.